Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.71 Billion EUR | 14.58% |
| 2022 | 8.47 Billion EUR | -31.18% |
| 2021 | 12.31 Billion EUR | 26.19% |
| 2020 | 9.76 Billion EUR | -40.87% |
| 2019 | 16.5 Billion EUR | -6.82% |
| 2018 | 17.71 Billion EUR | 235.13% |
| 2017 | 5.28 Billion EUR | -36.36% |
| 2016 | 8.3 Billion EUR | 12.15% |
| 2015 | 7.4 Billion EUR | -0.9% |
| 2014 | 7.47 Billion EUR | 18.0% |
| 2013 | 6.33 Billion EUR | -22.29% |
| 2012 | 8.15 Billion EUR | -27.97% |
| 2011 | 11.31 Billion EUR | 530.36% |
| 2010 | 1.79 Billion EUR | -56.59% |
| 2009 | 4.13 Billion EUR | 132.3% |
| 2008 | 1.78 Billion EUR | -57.99% |
| 2007 | 4.23 Billion EUR | -26.84% |
| 2006 | 5.79 Billion EUR | -41.62% |
| 2005 | 9.91 Billion EUR | -31.52% |
| 2004 | 14.48 Billion EUR | 6606.11% |
| 2003 | 215.97 Million EUR | -20.76% |
| 2002 | 272.54 Million EUR | -3.01% |
| 2001 | 281 Million EUR | 37.07% |
| 2000 | 205 Million EUR | -20.85% |
| 1999 | 259 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 16.95 Billion EUR | 94.67% |
| 2024 Q1 | 8.71 Billion EUR | -10.32% |
| 2023 Q3 | 7.99 Billion EUR | -38.68% |
| 2023 Q1 | 12.73 Billion EUR | 50.26% |
| 2023 Q2 | 13.03 Billion EUR | 2.34% |
| 2023 Q4 | 9.71 Billion EUR | 21.51% |
| 2023 FY | 9.71 Billion EUR | 14.58% |
| 2022 Q4 | 8.47 Billion EUR | 22.86% |
| 2022 Q1 | 10.1 Billion EUR | -17.92% |
| 2022 FY | 8.47 Billion EUR | -31.18% |
| 2022 Q3 | 6.89 Billion EUR | -51.88% |
| 2022 Q2 | 14.33 Billion EUR | 41.83% |
| 2021 Q1 | 13.91 Billion EUR | 42.57% |
| 2021 Q4 | 12.31 Billion EUR | 26.68% |
| 2021 Q2 | 11.92 Billion EUR | -14.29% |
| 2021 Q3 | 9.72 Billion EUR | -18.49% |
| 2021 FY | 12.31 Billion EUR | 26.19% |
| 2020 Q1 | 9.43 Billion EUR | -42.86% |
| 2020 Q4 | 9.76 Billion EUR | -38.88% |
| 2020 Q2 | 8.95 Billion EUR | -5.0% |
| 2020 FY | 9.76 Billion EUR | -40.87% |
| 2020 Q3 | 15.96 Billion EUR | 78.25% |
| 2019 Q4 | 16.5 Billion EUR | 144.82% |
| 2019 Q3 | 6.74 Billion EUR | -66.21% |
| 2019 Q2 | 19.95 Billion EUR | 186.9% |
| 2019 Q1 | 6.95 Billion EUR | -60.74% |
| 2019 FY | 16.5 Billion EUR | -6.82% |
| 2018 Q3 | 7.49 Billion EUR | -65.06% |
| 2018 Q1 | 14.2 Billion EUR | 168.69% |
| 2018 FY | 17.71 Billion EUR | 235.13% |
| 2018 Q4 | 17.71 Billion EUR | 136.42% |
| 2018 Q2 | 21.44 Billion EUR | 51.01% |
| 2017 FY | 5.28 Billion EUR | -36.36% |
| 2017 Q2 | 7.55 Billion EUR | -26.75% |
| 2017 Q3 | 10.87 Billion EUR | 44.07% |
| 2017 Q4 | 5.28 Billion EUR | -51.4% |
| 2017 Q1 | 10.3 Billion EUR | 24.09% |
| 2016 Q1 | 9.2 Billion EUR | 24.22% |
| 2016 FY | 8.3 Billion EUR | 12.15% |
| 2016 Q4 | 8.3 Billion EUR | 33.84% |
| 2016 Q3 | 6.2 Billion EUR | -44.59% |
| 2016 Q2 | 11.2 Billion EUR | 21.75% |
| 2015 Q1 | 7.44 Billion EUR | -0.33% |
| 2015 FY | 7.4 Billion EUR | -0.9% |
| 2015 Q3 | 4.92 Billion EUR | -50.88% |
| 2015 Q2 | 10.03 Billion EUR | 34.68% |
| 2015 Q4 | 7.4 Billion EUR | 50.31% |
| 2014 Q1 | 8.34 Billion EUR | 31.69% |
| 2014 Q4 | 7.47 Billion EUR | 70.85% |
| 2014 Q2 | 10.49 Billion EUR | 25.78% |
| 2014 Q3 | 4.37 Billion EUR | -58.3% |
| 2014 FY | 7.47 Billion EUR | 18.0% |
| 2013 Q3 | 4.26 Billion EUR | -59.32% |
| 2013 Q4 | 6.33 Billion EUR | 48.56% |
| 2013 FY | 6.33 Billion EUR | -22.29% |
| 2013 Q1 | 6.47 Billion EUR | -20.53% |
| 2013 Q2 | 10.47 Billion EUR | 61.79% |
| 2012 FY | 8.15 Billion EUR | -27.97% |
| 2012 Q4 | 8.15 Billion EUR | 0.0% |
| 2012 Q2 | 11.87 Billion EUR | 0.0% |
| 2011 Q4 | 11.31 Billion EUR | 0.0% |
| 2011 Q2 | 13.5 Billion EUR | 0.0% |
| 2011 FY | 11.31 Billion EUR | 530.36% |
| 2010 Q2 | 6.34 Billion EUR | 0.0% |
| 2010 Q4 | 1.79 Billion EUR | 0.0% |
| 2010 FY | 1.79 Billion EUR | -56.59% |
| 2009 Q4 | 4.13 Billion EUR | 0.0% |
| 2009 Q2 | 3.7 Billion EUR | 0.0% |
| 2009 FY | 4.13 Billion EUR | 132.3% |
| 2008 Q4 | 1.78 Billion EUR | 0.0% |
| 2008 FY | 1.78 Billion EUR | -57.99% |
| 2008 Q2 | 5.59 Billion EUR | 0.0% |
| 2007 Q4 | 4.23 Billion EUR | 0.0% |
| 2007 FY | 4.23 Billion EUR | -26.84% |
| 2007 Q2 | 5.57 Billion EUR | 0.0% |
| 2006 Q4 | 5.79 Billion EUR | 0.0% |
| 2006 Q2 | 8.79 Billion EUR | 0.0% |
| 2006 FY | 5.79 Billion EUR | -41.62% |
| 2005 Q4 | 9.91 Billion EUR | 0.0% |
| 2005 Q2 | 12.75 Billion EUR | 0.0% |
| 2005 FY | 9.91 Billion EUR | -31.52% |
| 2004 Q4 | 14.48 Billion EUR | 0.0% |
| 2004 FY | 14.48 Billion EUR | 6606.11% |
| 2004 Q2 | 189.38 Million EUR | 0.0% |
| 2003 Q2 | 199.02 Million EUR | 0.0% |
| 2003 FY | 215.97 Million EUR | -20.76% |
| 2003 Q4 | 215.97 Million EUR | 0.0% |
| 2002 FY | 272.54 Million EUR | -3.01% |
| 2002 Q4 | 272.54 Million EUR | 0.0% |
| 2002 Q2 | 259.7 Million EUR | 0.0% |
| 2001 FY | 281 Million EUR | 37.07% |
| 2000 FY | 205 Million EUR | -20.85% |
| 1999 FY | 259 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 57.31% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 67.627% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 709.269% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | -61158.988% |
| Novartis AG | 12.95 Billion USD | 25.033% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 5822.988% |